[
  {
    "ts": "2025-09-28T11:09:37+00:00",
    "headline": "Assessing AbbVie (ABBV) Valuation After FDA Filing for New Parkinson’s Drug Tavapadon",
    "summary": "If you have been following AbbVie (ABBV), the company’s latest move might sway your decision on whether to stick with or jump into the stock. AbbVie just submitted a New Drug Application to the FDA for tavapadon, its potential new treatment for Parkinson’s disease. The submission is backed by strong data from multiple Phase 3 trials. If approved, tavapadon could add diversity to AbbVie’s revenue base as it looks to expand further into neurology. This announcement comes at a time when AbbVie’s...",
    "url": "https://finance.yahoo.com/news/assessing-abbvie-abbv-valuation-fda-110937113.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "be30dfd9-b8fe-38d0-bbdd-2d1faeaf1f0e",
      "content": {
        "id": "be30dfd9-b8fe-38d0-bbdd-2d1faeaf1f0e",
        "contentType": "STORY",
        "title": "Assessing AbbVie (ABBV) Valuation After FDA Filing for New Parkinson’s Drug Tavapadon",
        "description": "",
        "summary": "If you have been following AbbVie (ABBV), the company’s latest move might sway your decision on whether to stick with or jump into the stock. AbbVie just submitted a New Drug Application to the FDA for tavapadon, its potential new treatment for Parkinson’s disease. The submission is backed by strong data from multiple Phase 3 trials. If approved, tavapadon could add diversity to AbbVie’s revenue base as it looks to expand further into neurology. This announcement comes at a time when AbbVie’s...",
        "pubDate": "2025-09-28T11:09:37Z",
        "displayTime": "2025-09-28T11:09:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-abbvie-abbv-valuation-fda-110937113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-abbvie-abbv-valuation-fda-110937113.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]